Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | SMARCA2 | P51531 | 2/20 | 0.49 |
| ▸ | SMARCA4 | P51532 | 2/20 | 0.49 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | MALT1 | Q9UDY8 | 7/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 3/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21611922 | 0.80 | SMARCA2 (0.49) | MAPTLMNASMARCA2SMARCA4HDAC4 | |
| SCHEMBL21612045 | 0.76 | CYP2C19 (0.53) | SMARCA2SMARCA4HDAC4HDAC6MALT1 | |
| SCHEMBL22125283 | 0.75 | SMARCA2 (0.60) | SMARCA2SMARCA4HDAC4HDAC6MALT1 | |
| SCHEMBL21614653 | 0.71 | SMARCA2 (0.60) | SMARCA2SMARCA4HDAC4HDAC6MALT1 | |
| SCHEMBL24258153 | 0.70 | SMARCA2 (0.59) | SMARCA2SMARCA4HDAC4HDAC6MALT1 | |
| SCHEMBL2641039 | 0.70 | SMARCA2 (0.59) | SMARCA2SMARCA4HDAC4HDAC6MALT1 | |
| SCHEMBL3616240 | 0.69 | SMARCA2 (0.66) | SMARCA2SMARCA4HDAC4HDAC6MALT1 | |
| SCHEMBL21611927 | 0.69 | PDK1 (0.40) | SMARCA2SMARCA4HDAC4HDAC6MALT1 | |
| SCHEMBL21611976 | 0.69 | SMARCA2 (0.49) | MAPTLMNAMEN1KMT2ASMARCA2 | |
| SCHEMBL16907423 | 0.69 | SMARCA2 (0.58) | MAPTSMARCA2SMARCA4MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11883387-B2 | PqsR inverse agonists | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2024-01-30 | — | — | US | disclosed |
| US-20210353606-A1 | PqsR INVERSE AGONISTS | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2021-11-18 | — | — | US | disclosed |
| EP-3818045-A1 | PQSR INVERSE AGONISTS | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2021-05-12 | — | — | EP | disclosed |
| WO-2020007938-A1 | PqsR INVERSE AGONISTS | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2020-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11883387-B2 | PqsR inverse agonists | QRFPR, P2RY11, QARS1 | MAPT 4857/4885LMNA 4546/4885MEN1 3460/4885 |
| US-20210353606-A1 | PqsR INVERSE AGONISTS | QRFPR, P2RY11, QARS1 | MAPT 4857/4885LMNA 4546/4885MEN1 3460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.